GlassScriptPhysician profile
Mary Beth Luca
NPI 1891805339
$3,088.44
in general payments reported to CMS, 2019-2025
14 companies · $445 in 2025
The $445 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $59.01 · 2021: $26.56 · 2022: $297 · 2023: $1,841 · 2024: $238 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,335 · Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,335.00 |
| Food and Beverage | $1,189.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,035.36 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $154.75 | 2019-2023 | Libtayo |
| Incyte Corporation | $147.14 | 2022-2023 | Opzelura |
| Janssen Biotech, INC. | $134.82 | 2022 | |
| Allergan, INC. | $133.84 | 2019-2021 | |
| Leo Pharma INC. | $119.08 | 2022-2025 | Anzupgo |
| Pfizer INC. | $89.63 | 2023-2024 | |
| Celgene Corporation | $74.19 | 2019 | |
| Biofrontera INC. | $50.05 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $40.77 | 2020 | |
| Lilly USA, LLC | $33.43 | 2023-2024 | Taltz |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Almirall LLC | $23.93 | 2025 | Seysara |
| Galderma Laboratories, L.P. | $20.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Beth Luca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.